Biocon
Biotechnology · BIOCON
Large CapHealthcareMature Stable
Siddharth Mittal
Managing Director and CEO · Pragmatic
Company DNA
Innovation-Led
About
Biocon is a Large Cap company in the Healthcare sector, listed on NSE as BIOCON. With a market cap of ₹63K Cr and revenue of ₹15K Cr, it is currently in the Mature Stable phase. Known for its Innovation-Led culture and Disruptor approach to innovation, the company operates at a Steady-Marathon pace. R&D-focused biotechnology entity that balances scientific innovation with global regulatory rigors, maintaining a culture of research-backed growth. Its strategic mandate: The company needs to pivot its complex biosimilars pipeline into high-margin global markets to combat commoditization in the generic segment.
FAQ
What kind of company is Biocon?
Biocon is a Large Cap Healthcare company (BIOCON) in the Mature Stable phase with a market cap of ₹63K Cr. It is classified as Innovation-Led in culture.
What is Biocon's culture and work environment like?
Biocon has a Innovation-Led culture with Disruptor innovation DNA and a Steady-Marathon pace of execution. Employee brand: Learning Ground. Customer relationship style: B2B-Enterprise. R&D-focused biotechnology entity that balances scientific innovation with global regulatory rigors, maintaining a culture of research-backed growth.
Who leads Biocon?
Biocon is led by Siddharth Mittal (Managing Director and CEO), a Pragmatic leader with 25 years of experience.
What are Biocon's financials?
Biocon reported revenue of ₹15K Cr in FY25 with a 5-year revenue CAGR of 23.3%. Operating margin: 10.8%. Market cap: ₹63K Cr.
Culture & Strategy
CultureInnovation-Led
InnovationDisruptor
PaceSteady-Marathon
PurposeMission-First
CustomerB2B-Enterprise
EmployeeLearning Ground
BrandTechnical-Expert
LifecycleMature Stable
R&D-focused biotechnology entity that balances scientific innovation with global regulatory rigors, maintaining a culture of research-backed growth.
Mandate
The company needs to pivot its complex biosimilars pipeline into high-margin global markets to combat commoditization in the generic segment.
The company needs to pivot its complex biosimilars pipeline into high-margin global markets to combat commoditization in the generic segment.
Financials
Revenue FY25₹15K Cr
PAT FY25₹1K Cr
Rev CAGR 5Y23.3%
OPM10.8%
NPM6.7%
ROE4.7%
ROCE3.7%
P/E78.8
Fwd P/E41.6
P/B1.8
D/E50
Mkt Cap₹63K Cr
Promoter54.1%
Institutional28.8%
Similar Culture
Could You Lead Biocon?
Take the Genome Benchmark →